Chronic Pain Market Size to Reach US$ 28.9 Billion by 2034 with CAGR of 2.9%

How big is the chronic pain market?

The chronic pain market reached a value of US$ 21.2 Billion in 2023 and expected to reach US$ 28.9 Billion by 2034, exhibiting a growth rate (CAGR) of 2.9% during ​2024-2034​.

The report offers a comprehensive analysis of the chronic pain market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market’s performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the chronic pain market.

Request a PDF Sample of the Report: https://www.imarcgroup.com/chronic-pain-market/requestsample

Chronic Pain Market Trends:

Chronic pain refers to long-term pain that persists beyond the usual healing period or coexists with a chronic illness. The chronic pain market is experiencing significant growth due to several key factors. Primarily, the market is largely fueled by the demographic trend towards an aging population, which is more susceptible to chronic conditions such as arthritis, lower back pain, and neuropathic pain. Advancements in medical research have led to the development of innovative pain management therapies, including minimally invasive procedures, targeted drug therapies, and neurostimulator techniques, aimed at offering highly effective and less addictive pain relief solutions. The growing awareness of the impact of chronic pain, coupled with the increasing preference for multidisciplinary pain management approaches, is driving the demand for comprehensive pain management solutions.

The chronic pain market is also benefiting from the integration of telehealth services, which have become particularly significant in the context of the COVID-19 pandemic, providing patients with chronic pain access to healthcare professionals without the need for in-person visits. Furthermore, the exploration of complementary and alternative medicine practices such as acupuncture, yoga, and mindfulness-based stress reduction techniques is gaining traction, offering additional avenues for pain management, and contributing to the market's expansion. The combined effect of these drivers is propelling the chronic pain market forward, with a focus on enhancing patient care and developing non-opioid pain management strategies.

Countries Covered:

• United States

• Germany

• France

• United Kingdom

• Italy

• Spain

• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario

• Historical, current, and future performance of the chronic pain market

• Historical, current, and future performance of various therapeutic categories in the market

• Sales of various drugs across the chronic pain market

• Reimbursement scenario in the market

• In-market and pipeline drugs

This report also provides a detailed analysis of the current chronic pain marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview

• Mechanism of Action

• Regulatory Status

• Clinical Trial Results

• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview

• Mechanism of action

• Regulatory status

• Clinical trial results

• Drug uptake and market performance

Competitive Landscape With Key Players:

The competitive landscape of the chronic pain market has been studied in the report with the detailed profiles of the key players operating in the market.

Some Key Players:

• Pfizer
• Biodelivery Sciences
• Astrazeneca
• Purdue Pharma

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=6612&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Browse Other Reports:

https://www.imarcgroup.com/diabetic-ketoacidosis-market

https://www.imarcgroup.com/diffuse-large-b-cell-lymphoma-market

https://www.imarcgroup.com/drug-resistant-epilepsy-market

https://www.imarcgroup.com/dyspepsia-market

https://www.imarcgroup.com/dystrophic-epidermolysis-bullosa-market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163